Ozempic at $274/Month: What the IRA Negotiation Means for Everyone

What the IRA Drug Negotiation Is

The Inflation Reduction Act of 2022 authorized Medicare to directly negotiate prices for certain high-cost drugs for the first time. Ozempic (semaglutide for type 2 diabetes) was among the drugs selected for negotiation. The negotiated price of $274 per month represents a roughly 70% reduction from the current list price and takes effect for Medicare Part D beneficiaries beginning January 1, 2027.

Important distinction: this negotiation applies to Ozempic (diabetes indication), not Wegovy (weight loss indication). However, the practical implications extend far beyond Medicare Part D diabetes patients.

Who Benefits Directly

Medicare Part D beneficiaries with type 2 diabetes: This is the direct target population. Combined with the IRA’s $2,000 annual out-of-pocket cap on Part D spending, the negotiated price means most Medicare patients will pay significantly less for Ozempic starting in 2027.

Potential off-label benefit: Some Medicare patients have been prescribed Ozempic (diabetes indication) when their physician also wanted to address weight loss. At $274/month, this off-label use becomes more financially viable, though it depends on the patient having a qualifying diabetes diagnosis.

The Ripple Effects on GLP-1 Pricing

The IRA negotiation’s impact extends beyond Medicare:

Benchmark pressure on commercial plans: When Medicare negotiates a drug to $274/month, commercial insurers use that as leverage in their own negotiations. Pharmacy benefit managers (PBMs) will point to the Medicare price as evidence that Novo Nordisk can sell Ozempic profitably at a much lower price point. This pressures commercial pricing downward over time.

Wegovy pricing implications: Novo Nordisk has already announced a Wegovy list price cut to $675 in 2027. The Ozempic negotiation reinforces the trend toward lower semaglutide pricing across the board. If the same active ingredient sells for $274/month under one brand name, it’s increasingly difficult to justify $1,349/month under another.

Compounding market impact: At $274/month, the IRA-negotiated Ozempic price is within the range of compounded semaglutide ($150–$400/month). For Medicare patients who previously used compounded semaglutide because brand-name was unaffordable, the negotiated price eliminates that need. For non-Medicare patients, the benchmark price creates expectations that brand-name semaglutide should be available in the $200–$300/month range, further pressuring the compounding market’s value proposition.

The Canadian Connection

Separately from the IRA negotiation, Novo Nordisk’s Canadian semaglutide patent expired January 4, 2026. At least nine companies (including Sandoz, Apotex, and Teva) have filed with Health Canada to sell generic semaglutide. Projected Canadian pricing: $100–$150/month.

While Americans cannot legally import prescription drugs from Canada in most cases, the emergence of global generic competition creates additional downward pricing pressure that will eventually reach the U.S. market. Combined with the IRA negotiation, the era of $900+ monthly semaglutide prices is ending.

Timeline: What Happens When

What Patients Should Do Now

If you’re on Medicare: The Bridge Program starts July 2026. Talk to your prescriber about transitioning to brand-name semaglutide when coverage begins. The January 2027 IRA price makes this even more attractive.

If you have commercial insurance: The IRA negotiation doesn’t directly set your price, but it creates negotiating leverage. Check whether your plan has updated its formulary or copay structure in response.

If you’re self-pay: The Wegovy pill at $149–$299/month is already price-competitive with compounding. As IRA pricing ripples through the market, expect additional price reductions across the board.